Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Siyuan Lu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0004-8169-8259; OpenAlex author ID A5101974236. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 10

  1. Ferroptosis Suppression by the M6A Reader IGF2BP1 Underlies Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.77048↗
  2. CPT1A through succinylation regulates the CTCF/LINC01503‒91aa feedback loop to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. First author DOI 10.1002/ctm2.70776↗
  3. Auranofin facilitates gemcitabine sensitivity by regulating TXNRD1-related ferroptosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2025.218058↗
  4. Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism. Co-author DOI 10.1053/j.gastro.2025.03.019↗
  5. Turning to immunosuppressive tumors: Deciphering the immunosenescence-related microenvironment and prognostic characteristics in pancreatic cancer, in which GL… Co-author DOI 10.1016/j.heliyon.2024.e36684↗
  6. A new approach: Evaluation of necroptosis and immune status enables prediction of the tumor microenvironment and treatment targets in pancreatic cancer. Co-author DOI 10.1016/j.csbj.2023.03.037↗
  7. Turning towards nonimmunoreactive tumors: Evaluation of cancer-associated fibroblasts enables prediction of the immune microenvironment and treatment sensitivi… Co-author DOI 10.1016/j.csbj.2022.07.029↗
  8. Pyroptosis-related lncRNA pairs to estimate the molecular features and prognostic outcomes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2022.101524↗
  9. Comprehensive analysis of the prognosis and immune infiltration landscape of RNA methylation-related subtypes in pancreatic cancer. Co-author DOI 10.1186/s12885-022-09863-z↗
  10. Turning up the heat on non-immunoreactive tumors: autophagy influences the immune microenvironment in pancreatic cancer. Co-author DOI 10.1186/s12920-022-01371-0↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ying‐Qin Zhu · 4 shared papers, 2024–2026 · strength 1.05
  2. De-Liang Fang · 4 shared papers, 2024–2026 · strength 1.05
  3. Mingjian Ma · 4 shared papers, 2024–2026 · strength 1.05
  4. Zhide Liu · 4 shared papers, 2024–2026 · strength 1.05
  5. Xianjun Yu · 6 shared papers, 2022–2025 · strength 0.95
  6. Qingcai Meng · 5 shared papers, 2022–2023 · strength 0.77
  7. Miaoyan Wei · 5 shared papers, 2022–2023 · strength 0.77
  8. Bo Zhang · 5 shared papers, 2022–2023 · strength 0.77
  9. Jie Hua · 5 shared papers, 2022–2023 · strength 0.77
  10. Xiao-Yu Yin · 2 shared papers, 2025–2026 · strength 0.56
  11. Si Shi · 3 shared papers, 2022–2025 · strength 0.50
  12. Jin Xu · 3 shared papers, 2022–2023 · strength 0.47
  13. Wei Wang · 3 shared papers, 2022–2023 · strength 0.47
  14. Jin Xu · 2 shared papers, 2022 · strength 0.30
  15. Xiao‐Yu Yin · 1 shared paper, 2026 · strength 0.28
  16. Yin-Hao Shi · 1 shared paper, 2024 · strength 0.22
  17. Xiao Yu Yin · 1 shared paper, 2024 · strength 0.22
  18. Rong Tang · 1 shared paper, 2025 · strength 0.19
  19. Yingna Liao · 1 shared paper, 2025 · strength 0.19
  20. Zhen Tan · 1 shared paper, 2025 · strength 0.19
  21. Mingming Xiao · 1 shared paper, 2025 · strength 0.19
  22. Qiong Du · 1 shared paper, 2025 · strength 0.19
  23. Zeyin Rong · 1 shared paper, 2025 · strength 0.19
  24. Wei Wang · 1 shared paper, 2025 · strength 0.19
  25. Jin Xu · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.